Safety and antitumor efficacy of 153Sm-EDTMP and docetaxel administered sequentially to patients with metastatic castration-resistant prostate cancer

Nuclear Medicine Communications

Volumn 35, Issue 1, 2014, Pages 88-94

  Borsò, Elisa ^a   Boni, Giuseppe ^a   Pastina, Ilaria ^b,e   Lorenzoni, Alice ^a,f   Cianci, Claudia ^b   Federici, Francesca ^b   Mazzarri, Sara ^a   Orlandini, Cinzia ^b   Francesca, Francesco ^c,g   Selli, Cesare ^a   Ricci, Sergio ^b   Rubello, Domenico ^d   Mariani, Giuliano ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Division of Medical Oncology Azienda USL2 Lucca   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e Misericordia Hospital   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g Town Hospital   (Italy)

Author keywords

153Sm EDTMP; Bone metastasis; Bone seeking radiopharmaceuticals for therapy; Docetaxel; Metastatic castration resistant prostate cancer; Sequential administration

Indexed keywords

ANTIEMETIC AGENT; DOCETAXEL; LEXIDRONAM SAMARIUM SM 153; MEDRONATE TECHNETIUM TC 99M; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; KAPLAN MEIER METHOD; LEUKOPENIA; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SAFETY; TAXOIDS;

EID: 84889252465     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000023     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29.
2. McRea LE, Karafin L. Carcinoma of the prostate: metastases, therapy, and survival: a statistical analysis of 500 cases. J Int Coll Surg 1958; 29:723-728.
3. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, et al. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60 (Suppl 1):1-6.
4. Fitzpatrick JM, Anderson J, Sternberg CN, Fleshner N, Fizazi K, Rébillard X, et al. Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. Crit Rev Oncol Hematol 2008; 68 (Suppl 1):S9-S22.
5. Seruga B, Tannock IF. Chemotherapy-based treatment for castrationresistant prostate cancer. J Clin Oncol 2011; 29:3686-3694.
6. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512. (Pubitemid 39315317)
7. Petrylak DP, Tangen CM, Hussain MHA, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351:1513-1520. (Pubitemid 39315318)
8. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis: a systemic review. Radiother Oncol 2005; 75:258-270.
9. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol 2005; 6:392-400. (Pubitemid 40753745)
10. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med 2005; 46:38S-47S. (Pubitemid 47619017)
11. Lam MG, de Klerk JM, van Rijk PP, Zonnenberg BA. Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases. Anticancer Agents Med Chem 2007; 7:381-397. (Pubitemid 47099046)
12. Paes FM, Serafini AN. Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain. Semin Nucl Med 2010; 40:89-104.
13. Paes FM, Ernani V, Hosein O, Serafini AN. Radiopharmaceuticals: when and how to use them to treat metastatic bone pain. J Support Oncol 2011; 9:197-205.
14. Seregni E, Padovano B, Coliva A, Zecca E, Bombardieri E. State of the art of palliative therapy. Q J Nucl Med Mol Imaging 2011; 55:411-419.
15. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 2007; 109:637-643. (Pubitemid 46190974)
16. Chiacchio S, Mazzarri S, Lorenzoni A, Nyakale N, Boni G, Borsò E, et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging 2011; 55:431-447.
17. Sartor O. Potential synergistic implications for stromal-targeted radiopharmaceuticals in bone-metastatic prostate cancer. Asian J Androl 2011; 13:366-368.
18. Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, et al. A dosecontrolled study of Sm-153-EDTMP in the treatment of patients with painful bone metastasis. Eur J Cancer 1997; 33:1583-1591.
19. Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double blind placebo-controlled clinical trial. J Clin Oncol 1998; 16:1574-1581. (Pubitemid 28175783)
20. Sartor O, Reid R, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004; 63:940-945. (Pubitemid 38596683)
21. Sinzinger H, Palumbo B, Ozker K. The Vienna protocol and perspectives in radionuclide therapy. Q J Nucl Med Mol Imaging 2011; 55:420-430.
22. 153Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2007; 34:1023-1030. (Pubitemid 46919554)
23. Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, et al. Phase I study of samarium-153 lexidronam with docetaxel in castrationresistant metastatic prostate cancer. J Clin Oncol 2009; 27:2436-2442.
24. Lipton A. Implications of bone metastases and the benefits of bone-targeted therapy. Semin Oncol 2010; 37 (Suppl 2):S15-S29.
25. Morgan G, Lipton A. Antitumor effects and anticancer applications of bisphosphonates. Semin Oncol 2010; 37 (Suppl 2):S30-S40.
26. Coleman R. The use of bisphosphonates in cancer treatment. Ann N Y Acad Sci 2011; 1218:3-14.
27. Coleman R, Cook R, Hirsh V, Major P, Lipton A. Zoledronic acid use in cancer patients: more than just supportive care? Cancer 2011; 55:411-419.
28. Distelmans W, Storme G. The effect of pretreatment with docetaxel (taxotere; RP 56976) on irradiated subcutaneous MA 16/C murine tumors. J Exp Clin Cancer Res 1999; 18:167-172. (Pubitemid 29359400)
29. Pradier O, Rave-Fränk M, Lehmann J, Lücke E, Boghun O, Hess CF, et al. Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CaSki). Int J Cancer 2001; 91:840-845. (Pubitemid 32178654)
30. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, Carducci MA, Tannock I, de Wit R, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25:3965-3970. (Pubitemid 47477275)